Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veracyte Inc VCYT

Healthcare Biotechnology
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory... see more

Recent & Breaking News (NDAQ:VCYT)

New Publication Demonstrates Ability of Veracyte's Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy

Business Wire October 13, 2021

Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

Business Wire October 12, 2021

New Clinical Utility Data Confirm Veracyte's Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis

Business Wire October 11, 2021

Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test's Ability to Improve Early Lung Cancer Assessment

Business Wire October 11, 2021

New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte's Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease

Business Wire October 6, 2021

Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy

Business Wire September 14, 2021

Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

Business Wire August 31, 2021

Veracyte Named a San Francisco Bay Area "Top Workplace" for Eighth Consecutive Year

Business Wire August 23, 2021

Veracyte Completes Acquisition of HalioDx

Business Wire August 3, 2021

Veracyte Announces Second Quarter 2021 Financial Results

Business Wire July 29, 2021

New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer

Business Wire July 27, 2021

Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth

Business Wire July 12, 2021

Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021

Business Wire July 8, 2021

Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion

Business Wire July 8, 2021

Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team

Business Wire July 1, 2021

New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte's Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer

Business Wire June 14, 2021

Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder

Business Wire June 4, 2021

CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences

Business Wire June 2, 2021

Veracyte to Present at Upcoming Investor Conferences

Business Wire June 2, 2021

Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth

Business Wire June 1, 2021